<DOC>
	<DOCNO>NCT00326287</DOCNO>
	<brief_summary>The purpose study compare clinical cure rate ( ratio clinically cure patient total number patient ) ceftobiprole medocaril versus comparator treatment patient community-acquired pneumonia .</brief_summary>
	<brief_title>Ceftobiprole Treatment Patients With Community-Acquired Pneumonia</brief_title>
	<detailed_description>Ceftobiprole medocaril cephalosporin antibiotic anti-MRSA ( Methicillin-Resistant Staphylococcus Aureus ) activity . Ceftobiprole medocaril yet approve treatment community-acquired pneumonia . This randomized , double-blind , multicenter study ceftobiprole medocaril plus placebo versus comparator ass effectiveness safety ceftobiprole medocaril patient community-acquired pneumonia . The patient randomize ceftobiprole medocaril plus placebo comparator . Patients meet specified criterion may switch alternative oral treatment . The primary endpoint clinical cure rate among patient treat ceftobiprole test cure visit . The patient receive either ceftobiprole medocaril plus placebo comparator .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Ceftriaxone</mesh_term>
	<mesh_term>Ceftobiprole</mesh_term>
	<mesh_term>Ceftobiprole medocaril</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>Patients suffer communityacquired pneumonia severe enough require hospitalization Female patient must postmenopausal least 1 year , surgically sterile , practice effective method birth control entry throughout study Patients know suspected hypersensitivity relate antibiotic medication Treatment experimental drug within 30 day enrollment Prior enrollment study study ceftobiprole medocaril</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Community-Acquired Pneumonia</keyword>
	<keyword>Cephalosporins</keyword>
	<keyword>Methicillin-Resistant Staphylococcus Aureus</keyword>
</DOC>